Member Info for JRDC

Novacyt a pure covid play, built up on 1980's PCR technology. I think thats why institutions aren't interested, even at these prices. The fact is nova still haven't put their cash to good use and diversified or added complimentary acquisitions is concerning - perhaps they're waiting for GM to go and let the new guy drive the vision, or potential suitors aren't keen on how the company is being run. If a new 2nd gen vaccine appears, or some sort of cheap at home treatment is released it may mean less emphasis on testing.

The bod have killed any excitement I had for this share, though hoping for one last hurrah at £5-£6

Im as positive for avacta as anyone on here, but being on the frame work that allows purchasing for professional use by clinical organisations does not mean HUA is guaranteed nor imminent. It's still beyond avactas control, they might meet the criteria to submit for HUA but the decision makers aren't duty bound to accept, and if they're the same ones who approved innova, acon and orient gene, and barely allowing surescreen to scrape through, Im not putting too much hope on it.

Europe home approval and orders, perhaps via Spain, airlines, maybe US is what I'm looking for. If something comes from UK orders, whether thats through govt or finding them in the middle aisles of aldi for self testing then great, but I'm not fussed if we don't hear a word, and with the way the govt has ****ed over novacyt, mologic and Abingdon, as well as stringing omega along, large part of me thinks fook em, they can stick with the Chinese cack. Avacta tests are currently selling, might not be anywhere near the 5m units a month we're hoping for, but there's still a long way to go in this covid game, we're not even at half time yet with only 9% of third world with 1 jab. If score still 0-0, well we have our super sub - Ava early read out due end of the year and phase 1 results by q2.

"The company has the capacity to manufacture approximately 7 million tests per week, with plans to increase this to 14 million per week by the end of December."

I guess this is where omega steps in

GM has said in past that "shareholders are not his priority", in fact he probably sees us as a huge inconvenience (unless they need funding), as he's leaving I'm quite sure the new guy will be well aware of where GM was lacking and I'm willing to give them the benefit. Look at how the EUA bod in a recent rns pointed out "notes that the share price remains below the 26.5p price at which the $20m private placement", and promptly rose, even something small along those lines that shows the board cares about investors would help and make it more risky for those betting against the company

The ex-ceo of Omega seemed to think back in June there won't be a sovereign test (nicked from twatcher on ODX chat) , but instead the market opened up to multiple companies (I presume with HUA)

Bojo said they're working with UK industry, and most of the 112 or so listed are UK based (strange no odx or mologic listed though) so perhaps that is what he meant. Nova have had orders via the framework despite dispute with DHSC,

Guess it's this one

https://bidstats.uk/tenders/2021/W15/748945953

If Als brother drives a Ford transit we should tender for it.

Endorsed by

Christoph Schultes
out of network
3rd+
Global Program Lead Oncology (Late Development) at Merck Group

I'm assuming you're referring to me. 'the other share' is at the beginning of their journey, which will take 2 - 3 years to fully develop to a solid multi billion pound mcap, many holders here, who may not admit it for fear of rampers like you getting on their case, will be out of nova as soon as they get a decent price. After all, we're here to make money and if theres one thing this share has taught me its don't be greedy and take your profit.

Just shows the influence the dispute is having when even best H1 sales aren't enough (granted h2 will be lower). Looks like the market is valuing nova differently to how PIs are. I'm not selling for a loss, avr £4.30 now and willing to wait 6 months for dispute to be settled, but also mindful that £100m revenue will probably not push the SP back to the £9 I paid at its height. Mms have played a blinder, and I'll need the cash sooner than they will.

"If a manufacturer has developed a test with an unforeseen advantage, we reserve the right to review and permit submission for validation if the scientific consensus supports the claim."

I wonder if developing the most accurate real world lateral flow test counts, or that affimers can be tweaked in weeks to test against new variants and its a fully UK owned technology. Or we haven't sued the DHSC yet.

I thought that Bluelight but I believe the contract has a clause excluding interest on payments in dispute from researching, and even if dispute goes against DHSC penalties cannot be applied (was lifted from another contract but as they use fairly standard contracts it will apply here too). Therefore nova will be looking to resolve this asap, whereas before i thought they might be happy to drag it out.

The EUA for orient and innova has been extended until Jan, but specifies not for daily testing, only track n trace. Is this a new term? The guys on nova seem seem to think so but I thought that term existed already.

Nova need to shake this idea they're just a covid play (which they are at present - take any covid related revenue away and they're back to pennies) to get a sensible valuation - look at abcam for example, £3.3bn mcap on £260m revenue and £12.5m profit, because they're diversified and have an attractive pipeline. Resolution of the DHSC dispute is the first step as it will potentially free up millions in cash for acquisitions, and probably double the SP if its all in our favour.

Just looks like its the dispute holding things up, figures look pretty damn good. Would like to see that settled by end of the year or early Q1 22, maybe that will be the focus of the new chap.

I'm most interested to see what nova are doing with all their cash. If they're just sitting on it then maybe they're aiming for a buyout or resolution of the dispute first before looking at further acquisitions (in which case they should say). Hopefully they're in talks with 1 or 2 possible targets. Can't see this ever dipping under £3 again, so only upside from here imo

Looks like all the complainers are wannabe traders and gamblers, not well researched investers. AS has given us the milestones, the LFT is on the market and now he's trying to ramp up production to meet significant demand. I'm here for the long term, the ADC market is going to be massive, affimers have huge potential over antibodies and nanobodies - our closest competition in the form of affibodies is no more advanced, but justifies a £3bn mcap for abcam on little over £10m profit, yet affimers look to be even more versatile - just read up on some of the lab work done on imaging, or pre clinical work delivering drugs to target tumours with the likes of iksuda. Avacta now have their affimer tech in the LFT which happens to be the most accurate in the world as a showcase for it.

We'll no doubt see further licensing deals for affimers which is where the real money will be made (and dismissed as jam RNSs). As the world moves away from using antibodies and nanobodies derived from animals and all the drawbacks with it, they'll be looking at something to replace it with. Yes the mms have had fun taking the **** out of people who have just found out what a stop loss is, or have panic attacks when the SP drops, but with the pipeline avacta has for the next 2-3 years there's no other company I'd feel more comfortable having 90% of my SIPP and ISA in. At these prices I'm adding whatever I can.

Apologies if posted before. List of all testing companies, if anyone feeling particularly bored they could check which ones are using our kits

http://qna.files.parliament.uk/qna-attachments/1347579/original/HL2097%20TABLE.docx

If you look at the accepted tests they're mostly Chinese too. Including that Lepu device which was tested recently and found to be pretty much a fake device, also recalled by the fda. I don't think their testing procedures are any better than ours. Hope they didn't reject surescreen simply because it's British

https://www.google.com/url?sa=t&source=web&rct=j&url=https://ec.europa.eu/health/sites/default/files/preparedness_response/docs/covid-19_rat_common-list_en.pdf&ved=2ahUKEwizmqLj_rTyAhVwRUEAHUEnBlAQFnoECAsQAQ&usg=AOvVaw2x0Ehp66OU3dvXmr63GOmj

Is 2022-01 the expiry date? Does this mean shelf life of 6 months or they've been stockpiling since Jan, or were the boxes and paraphernalia produced months ago?

I've reported every NDN post now, I suggest everyone do the same